title: Candidate ALS therapeutics motor toward "in vitro clinical trials".
abstract: Conducting drug discovery efforts in patient- and disease-specific cells can maximize their likelihood of success. In this issue of Cell Stem Cell, Yang et al. (2013) demonstrate the power of lineage-specific cell-based drug screens by identifying a compound that promotes survival of stem-cell-derived ALS mutant motor neurons.
authors.affiliation: Institute for Cell Engineering, Department of Neurology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
authors.forename: Yong Jun
authors.initials: YJ
authors.lastname: Kim
authors.forename: Gabsang
authors.initials: G
authors.lastname: Lee
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D000818:Animals; D053595:Embryonic Stem Cells / Q000166:cytology*; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors*; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors*; D009046:Motor Neurons / Q000166:cytology* / Q000187:drug effects*; D047428:Protein Kinase Inhibitors / Q000032:analysis* / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; C117090:MAP4K4 protein, human; D017346:Protein Serine-Threonine Kinases; D038362:Glycogen Synthase Kinase 3